Biotechnology and Pharmaceuticals Report

The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report, a report offering a timely review of the sector to serious investors and industry executives. This 27-page feature contains industry commentary through in-depth interviews with 4 leading Analysts; and top management from 4 Sector Firms. Topics covered: Orphan Drug and Biologics Manufacturing - U.S. and European Drug Pricing - Biotechnology and Pharmaceutical Companies Valuation - Domestic Regulatory Uncertainty

Additional Information

Topics covered:

Orphan Drug and Biologics Manufacturing
U.S. and European Drug Pricing
Biotechnology and Pharmaceutical Companies Valuation
Domestic Regulatory Uncertainty

Companies covered:

Eli Lilly (LLY)
InterMune's (ITMN)
Abbott (ABT)
Acura Pharmaceuticals (ACUR)
Alexion (ALXN)
Amgens (AMGN)
AstraZeneca (AZN)
Biogen Idec (BIIB)
Biomarin (BMRN)
Bristol-Myers (BMY)
Celgenes (CELG)
Dendreon's (DNDN)
Gileads (GILD)
GlaxoSmithKline (GSK)
Human Genome Sciences' (HGSI)
Incyte (INCY)
International Stem Cell (ISCO)
J&J (JNJ)
Marshall Edwards (MSHL)
Merck (MRK)
Neurocrine (NBIX)
Novartis (NVS)
Pfizer (PFE)
Sanofi (SNY)
Targacept (TRGT)
Tranzyme, Inc. (TZYM).